Brought to you by 
Existing investors put another $30mm into Calistoga
25 Feb 2021
Executive Summary
Calistoga Pharmaceuticals (hematological cancers and inflammation) raised $30mm through its Series B round from existing backers Alta Partners, Amgen Ventures, Frazier Healthcare, and Three Arch Partners. To date, the company has raised over $56mm. The latest funds will go towards development of Calistoga's clinical-stage isoform-selective PI3K inhibitors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Existing investors put another $30mm into Calistoga
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice